Finoriq research workspace
Xeris Biopharma Holdings, Inc. (XERS) Institutional Holdings & 13F Ownership
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in. Review XERS institutional holders, 13F ownership, and position changes on Finoriq.
Company Snapshot
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
- Company
- Xeris Biopharma Holdings, Inc. (XERS)
- Ticker
- XERS
- Market Cap
- $1.5B
- Latest Price
- $8.615
- Industry
- Biotech & Pharma
Xeris Biopharma Holdings, Inc. (XERS) Top Institutional Holders
Top current 13F holders indexed for Xeris Biopharma Holdings, Inc. (XERS). Latest period 2026-03-31.
| Rank | Investor | Value | Portfolio | Filing |
|---|---|---|---|---|
| 1 | Joel GreenblattCIK 0001510387 | $250,891 | 0.0% | Filing2026-05-15 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.